Background: Acute Myeloid leukemia (AML) is the most prominent acute leukemia in adults. In the United States, we experience over 20,000 cases per year. Over the past decade, improvements in the diagnosis of subtypes of AML and advances in therapeutic approaches have improved the outlook for ...
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336. Article CAS Google Scholar ...
Acute myeloid leukemia (AML) is a cancer that starts in the cells of your bone marrow that make different types of blood cells. It usually starts in a precursor cell to one type of white blood cell. Many of the symptoms of AML are nonspecific, which means they can be caused by several...
In younger adults with newly diagnosed acute myeloid leukemia (AML), anthracycline dose intensification during induction may improve complete remission (CR) rates; however, an improvement in overall survival (OS) in a randomized trial ha... HF Fernandez,Z Sun,MR Litzow,... - 《Journal of Clini...
AML-068- Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but ... AML-068- Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and ...
Gale RP, Cline MJ (1977) High remission induction rate in acute myeloid leukemia. Lancet I:497–499 Google Scholar Gale RP (1979) Advances in the treatment of acute myelogenous lcukemia. N Engl J Med 300:1189–1192 PubMed Google Scholar Galton DAG, Kay HEM, Reizenstein P, Penchansky...
Mutations of Nucleophosmin (NPM1) are the most common genetic abnormalities in adult acute myeloid leukaemia (AML), accounting for about 30% of cases. NPM1-mutated AML has been recognized as distinct entity in the 2017 World Health Organization (WHO) cla
Acute myeloid leukemia (AML), the second most common leukemia in children, is hard to treat and has a five-year survival rate of just 65 to 70%, according to the American Cancer Society. While immunotherapies like monoclonal antibodies or CAR T-cell therapy are effective for certain blood ca...
Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable hematological malignancy that affects the myeloid cell progenies and challenges patients of all ages but mostly occurs in adults. Although several therapies are available inc
理论上讲,Hubbell的疫苗技术可以击溃一切肿瘤,真正实现"一物降万病魔"的宏愿。参考文献：Slezak, A. J., et al. (2024). Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia. Blood Advances. doi.org/10.1182/bloodadvances.2023012529.